An observational study in Bronchiectasis, sponsored by Nisanur Tutuş. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-24.
Sponsored by Nisanur Tutuş · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Bronchiectasis with a site in Turkey — 10 open to participants now, 11 under way, 2 of them phase 3. Bronchiectasis · Turkey.
Among the 36 studies in Bronchiectasis with a site in Turkey, this one is the 5th largest by planned enrollment of the 12 observational ones that give a count, is one of 7 that started in 2025, is one of 12 observational ones, reaches primary completion later than 0 of the 10 other live ones, and was the 30th registered.
405 studies on the registry are indexed under Bronchiectasis; 126 are open to participants now.
Browse Bronchiectasis studies →10 of the 36 studies in Bronchiectasis with a site in Turkey are open now. Recruiting first, the newest first:
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18+ · Healthy volunteers
Elif Kabasakal · Sites in Turkey
Ages 18–30
AstraZeneca · Sites in Turkey, United States, Argentina and 22 more countries
Ages 12+
Atlas University · Sites in Turkey
Ages 7–18 · Healthy volunteers
Boehringer Ingelheim · Sites in Turkey, United States, Argentina and 43 more countries
Ages 12+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 94 Bronchiectasis studies recruiting now, 51 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 13 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 7 started in 2025.
This study's planned enrollment of 64 is below the median of 170 across 138 observational studies indexed under Bronchiectasis.
Median enrollment 60 across the 24 interventional studies, 60 across the 12 observational. Of the 23 that completed or were terminated, 3 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 36 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Nisanur Tutuş as lead sponsor.
Nisanur Tutuş has 1 study filed under Bronchiectasis — fewer than ten, so there is no comparison to draw.
6 of the studies in Bronchiectasis with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06872892Phase 3Boehringer IngelheimThe AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | 2027-06-15 |
| NCT03561818Istanbul Medipol University HospitalComparison of PR Efficiency in Home-based With Hospital-based PR in Bronchiectasis | 2026-12-30 |
| NCT07805174Saglik Bilimleri UniversitesiHigh-Intensity Interval Exercise in Bronchiectasis Patients | 2026-12-31 |
| NCT06631261Hacettepe UniversityCardiopulmonary Responses to 6-Minute Stepper Test in Bronchiectasis Versus Healthy Controls | 2027-01-18 |
| NCT07317531Istanbul Demiroglu Bilim UniversityEffects of Expiratory Muscle Training Added to Pulmonary Rehabilitation in Patients With Bronchiectasis | 2027-02-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 36 studies in Bronchiectasis with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates the relationship between expiratory muscle strength and clinical outcomes such as disease severity, hospital admissions, and quality of life in individuals with bronchiectasis.
This study aims to examine the relationship between expiratory muscle strength and clinical outcomes such as disease severity, hospital admission history, and quality of life in individuals with bronchiectasis. Effective coughing is a critical physiological reflex for airway clearance; however, the relationship between expiratory muscle strength and cough effectiveness in the bronchiectasis population has not been clearly established. Identifying expiratory muscle weakness as a potential contributor to increased symptom burden and impaired airway clearance may improve clinical understanding and support the development of targeted physiotherapy interventions. The findings of this study could serve as a foundation for future interventional research in pulmonary rehabilitation and respiratory muscle training for this population.
Süreyyapaşa Chest Diseases and Chest Surgery Training and Research Hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Respiratory Muscle Strength
Respiratory muscle function will be assessed by measuring maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) in the sitting position using a mouth pressure device (MEC PFT Systems Pocket-Spiro).
Time frame: Baseline
Modified Medical Research Council Dyspnea Score
Modified Medical Council Dyspnea score will rate the sensation of dyspnea as the person perceives it.The severity of dyspnea is rated on a scale of 0 to 4."0 point" means no dyspnea perception and "4 point" means severe dyspnea perception.
Time frame: Baseline
Leicester Cough Questionnaire
This is a short questionnaire that assesses quality of life, particularly for chronic cough. It is relatively easy to administer. The Leicester Cough Questionnaire consists of nineteen questions assessing three different areas: physical, social, and psychological. Scores for the LCQ include mean scores for each domain (ranging from 1 to 7) and a total score calculated as the sum of the domain scores (ranging from 3 to 21). Higher scores indicate better quality of life.
Time frame: Baseline
Bronchiectasis Severity Index
The Bronchiectasis Severity Index (BSI) will be used to determine disease severity. This index examines nine parameters: age, body mass index, % predicted FEV1, hospitalizations due to exacerbations in the last 2 years, number of exacerbations in the previous year, level of dyspnea, colonization by Pseudomaonas and other microorganisms, and radiological findings. These scores classify patients into mild (0-4 points), moderate (5-8 points), and severe (9 points and above) groups and identify patients at risk of death, hospitalization and exacerbations.
Time frame: Baseline
Hospital Anxiety Depression Scale
This is a 14-item scale developed by Zigmond and Snaith. Seven of these items assess anxiety symptoms, and seven assess depression symptoms. The items in the scale are assessed using a 4-point Likert scale and are based on a scoring system ranging from 0 to 3. Scores range from 0 to 21 for each subscale and can be summed to yield a total anxiety-depression score of up to 42. Higher scores indicate increased symptom severity, while a cut-off score of 8 indicates high levels of depression and anxiety symptoms.
Time frame: Baseline
Fatigue severity scale
Individuals' fatigue levels will be assessed using the Fatigue Severity Scale (FSS). The FSS consists of 9 questions scored on a 7-point Likert scale, indicating a perceived level of fatigue that may require medical attention. It is a valid and reliable instrument, with a score of 7 being associated with greater fatigue.
Time frame: Baseline
Spirometric measurements (Forced vital capacity)
It is used to evaluate respiratory functions. It is evaluated with a spirometer. Forced vital capacity (FVC): the maximum amount of air that can be forcibly exhaled from the lungs after fully inhaling. It can be recorded in percentages or liters.
Time frame: Baseline
Spirometric measurements (First second forced expiratory volume)
It is used to evaluate respiratory functions. It is evaluated with a spirometer. First-second forced expiratory volume (FEV1): the amount of air that can be exhaled with force in 1 second. It can be recorded in percentages or liters.
Time frame: Baseline
Spirometric measurements (FEV1/FVC ratio)
It is used to evaluate respiratory functions. It is evaluated with a spirometer. It is calculated by dividing FEV1 by FVC. It is expressed as a percentage.
Time frame: Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Dec 2025, 4 months later.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.